SOPHiA GENETICS technology to aid research associated with hereditary cancers and disorders
SOPHiA GENETICS technology aids NOMAD Genetics in the advancement of its cancer research...
Leader in data-driven medicine will discuss progress in the adoption of exome and...
As a leader in data-driven medicine, SOPHiA GENETICS lends its expertise to support White House Cancer Moonshot
Microsoft’s Deputy Chief Technology Officer to be appointed at Annual Shareholders’ Meeting BOSTON...
SOPHiA GENETICS leaders will talk onsite about the company’s cutting-edge SOPHiA DDM™ Platform
SOPHiA DDMTM deep-learnings algorithm will help determine HRD status of tumors for Institute of Oncology Ljubljana researchers
Natural State Laboratories Chooses SOPHiA GENETICS to Help Launch their In-House Hereditary Cancer Testing
SOPHiA GENETICS technology will help increase cancer research abilities
In just one year of using SOPHiA DDM™ HRD, Dasa reaches 2,000 samples analyzed BOSTON and...
Strong growth momentum and efficient expense execution continues
SOPHiA GENETICS expands footprint in India as Unipath Specialty Laboratory Limited is now live on SOPHiA DDM™ HRD Solution
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CEST.